Exclusive: Perceptic, a startup automating drug discovery end-to-end for Big Pharma, emerges from stealth with $12 million in seed funding
Perceptic, a startup founded by former Palantir executives, has launched an AI platform for drug development and secured $12 million in seed funding. The company aims to streamline the drug discovery process by integrating various AI tools and data sources used by pharmaceutical companies. With its software already in use by top-tier firms, Perceptic is positioning itself as a comprehensive solution for the complexities of drug development.
- ▪Perceptic has developed an end-to-end AI platform for drug development.
- ▪The startup raised $12 million in seed funding led by Accel.
- ▪Perceptic's software is already being utilized by multiple pharmaceutical companies, including CSL.
- ▪The platform aims to connect various AI tools and data sources to improve drug discovery efficiency.
- ▪Perceptic focuses on scouting external assets, selecting clinical trial indications, and building a data foundation for trial design.
Fortune files mainly under business. We currently carry 643 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Fortune |
| Canonical URL | https://fortune.com/2026/05/26/exclusive-perceptic-a-startup-automating-drug-discovery-end-to-end-for-big-pharma-emerges-from-stealth-with-12-million-in-seed-funding/ |
| Publication time | Tue, 26 May 2026 13:00:00 +0000 |
| Retrieval time | 2026-05-26T13:17:49.438Z |
| Last seen | 2026-05-26T13:17:49.438Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | z2Kxebqt2hqi |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
A trio of former Palantir executives who helped spearhead that company’s Life Sciences practice have founded a startup called Perceptic that is building an end-to-end AI platform for drug development, handling everything from drug discovery to clinical trial design. The company emerged from stealth today and announced a $12 million seed funding round. London-based venture capital firm Accel led the funding round, alongside Air Street Capital and Elder Gull. The company’s valuation following the funding round was not disclosed. Perceptic said its software is already being used by multiple top-tier pharmaceutical companies, though it was only allowed to name CSL, the Australian biotechnology company. In the past two years, numerous startups have sprung up to use AI to speed drug discovery.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Fortune.
Discussion
0 commentsMore from Fortune
